Cullinan Therapeutics, Inc. (CGEM) Financial Statements
Free cash flow over the same period: -$159.3M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
CGEMCullinan Therapeutics, Inc.Follow CGEM — free
—
Price chart with a free account
- Market cap
- 924.8M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 5 Nov, in 11 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|
| Research & development | 57.8 | 91.9 | 148.2 | 142.9 | 187.4 | 171.5 | |
| Operating income | -68.0 | 144.6 | -191.1 | -196.9 | -241.6 | -221.8 | |
| Pre-tax income | -67.5 | 151.3 | -169.2 | -167.5 | -219.9 | — | |
| Income tax | — | 42.1 | -14.1 | 0.1 | 0.0 | — | |
| Net income | -65.6 | 111.2 | -153.2 | -167.4 | -219.9 | -204.7 | |
| Diluted EPS ($) | -1.52 | 2.38 | -3.69 | — | — | — | |
| Diluted shares (mn) | — | 46.6 | 41.5 | — | — | — |
USD millions · SEC XBRL
Cullinan Therapeutics, Inc. — questions
- What is Cullinan Therapeutics, Inc.'s net income?
- -$204.7M over the twelve months to 2026-06-30.
- What is Cullinan Therapeutics, Inc.'s free cash flow?
- -$159.3M over the twelve months to 2026-06-30.
Every figure on this page comes from Cullinan Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.